Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024, page-29

Hi FreeFromStyle,

I would rather expect Opthea‘s two P3 trials to be reported as a single make-or-break announcement as you say.

Reason being the real world experience with the two most recent wAMD drugs:

Vabysmo (farizimab, ROG):
LUCERNE reported primary completion date Oct 5, 2020
TENAYA reported primary completion date Oct 26, 2020
Both reported topline data the same day on Jan 25, 2021, that‘s three months post TENAYA‘s PCD.

Beovu (brolucizumab, NOVN):
HARRIER reported primary completion date Apr 5, 2017
HAWK reported primary completion date Apr 22, 2017
Both reported topline data the same day on Jun 20, 2017, that‘s two months post HAWK‘s PCD.

So, assuming ShORe announcing full enrollment later in April and primary completion date being 52 weeks later, we could assume topline data for both COAST and ShORe to be reported simultaneously in the June/July 2025 time frame.